background image

News & Media

Press Release

MindMed Provides Corporate Update and 2023 Outlook

– Company positioned for key MM-120 Phase 2b data readout in GAD and Phase 2a data readout in ADHD in late 2023 – Company to initiate first clinical trial of MM-402 in 2023 – Cash runway to fund current operating plan into first half of 2025 – Company to host a virtual analyst and investor day in […]

Read More